Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy – Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

(2021) Luis Paz-Ares et al.   LANCET ONCOLOGY

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

(2021) D.R. Spigel et al.   ANNALS OF ONCOLOGY

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

(2021) Taofeek K. Owonikoko et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

(2021) Jeffrey A Bogart et al.   JOURNAL OF CLINICAL ONCOLOGY

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

(2020) Jonathan W Goldman et al.   LANCET ONCOLOGY

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

(2019) Neal E. Ready et al.   Journal of Thoracic Oncology

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

(2019) Hyun Cheol Chung et al.   Journal of Thoracic Oncology

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

(2018) Neal Ready et al.   Journal of Thoracic Oncology

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

(2017) Corinne Faivre-Finn et al.   LANCET ONCOLOGY

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Predicting the restricted mean event time with the subject's baseline covariates in survival analysis

(2013) L. Tian et al.   BIOSTATISTICS

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

(2010) Stephen B. Edge et al.   ANNALS OF SURGICAL ONCOLOGY